Superworth

Madrigal Pharmaceuticals profit margin MDGL

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
−25.3%
Operating margin, 12 months
−25.1%
Net margin on a year earlier
+29.4 pts
Peer median
15.0%

Over the twelve months to Jun 30, 2026, Madrigal Pharmaceuticals kept −25.3% of its revenue as net profit, with an operating margin of −25.1%.

The median for 10 large drugmakers of a similar size is 15.0%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−30.1%−31.3%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−25.3%+29.4 pts−25.1%
Q1 FY26−27.3%n/a−27.7%
Q4 FY25−30.1%n/a−31.3%
Q3 FY25−39.0%n/a−41.5%
Q2 FY25−54.7%n/a−60.1%
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.

CompanyProfit margin
MDGLMadrigal Pharmaceuticals−25.3%
BMRNBiomarin Pharmaceutical2.1%
CORTCorcept Therapeutics6.6%
PTGXProtagonist Therapeutics29.4%
TGTXTG Therapeutics55.2%
ALKSAlkermes plc.4.0%
JAZZJazz Pharmaceuticals20.4%
AMRXAmneal Pharmaceuticals5.0%
LGNDLigand Pharmaceuticals67.9%
KNSAKiniksa Pharmaceuticals International9.6%
INDVIndivior Pharmaceuticals26.7%
Peer median15.0%

Where Madrigal Pharmaceuticals ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Madrigal Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.